OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
April 10, 2023
Webinar Date/Time: Friday, April 28, 2023 at 11am EDT | 10am CDT | 8am PDT
April 07, 2023
Lonza and ABL Bio are collaborating on the development and manufacture of bispecific antibody product.
April 04, 2023
Webinar Date/Time: Thursday, May 11th, 2023 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
April 03, 2023
Webinar Date/Time: Tue, May 23, 2023 11:00 AM EDT
Despite the advantages intensified processes can offer developers, there are still some obstacles to overcome before broader application of new technologies will be implemented.
Impurities and batch-to-batch variability present the biggest challenges.
April 02, 2023
New child-friendly treatment options and initiatives are improving the outlook of children living with HIV in Europe.
FDA has spurred investment to create and develop 600 therapies.
Decreasing vein to vein time saves lives.
March 30, 2023
Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.